Biogen Idec submits BLA for hemophilia B treatment

Biogen Idec has submitted a biologics license application to the FDA for the use of recombinant factor IX Fc fusion protein as a treatment for hemophilia B. The company said a decision from the agency could come this year. Biogen Idec also said it is preparing to submit a similar application for a treatment for hemophilia A in the first three months of 2013.

View Full Article in:

Boston Globe (tiered subscription model), The · PharmaBiz.com (India)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC